Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C36H49Cl2N6O6S.Cl.ClH |
Molecular Weight | 836.696 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.[Cl-].CC1=NC2=C(C=CC=C2OCC3=C(Cl)C=CC(=C3Cl)S(=O)(=O)NC4(CCOCC4)C(=O)N5CCN(CC5)C(=O)[C@@H](N)CCC[N+](C)(C)C)C(C)=C1
InChI
InChIKey=QIAWOUUTKDMGTE-UJXPALLWSA-M
InChI=1S/C36H49Cl2N6O6S.2ClH/c1-24-22-25(2)40-33-26(24)8-6-10-30(33)50-23-27-28(37)11-12-31(32(27)38)51(47,48)41-36(13-20-49-21-14-36)35(46)43-17-15-42(16-18-43)34(45)29(39)9-7-19-44(3,4)5;;/h6,8,10-12,22,29,41H,7,9,13-21,23,39H2,1-5H3;2*1H/q+1;;/p-1/t29-;;/m0../s1
Fasitibant (MEN-16132) is a non-peptide sulfonamide-containing bradykinin hB2 receptor antagonist. It inhibits pro-inflammatory response in vitro and alleviates inflammatory hyperalgesia in rodent models of osteoarthritis. Menarini Group was developing fasitibant for the treatment of osteoarthritis. Fasitibant development has been discontinued.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Design and synthesis of novel sulfonamide-containing bradykinin hB2 receptor antagonists. 2. Synthesis and structure-activity relationships of alpha,alpha-cycloalkylglycine sulfonamides. | 2007 Feb 8 |
|
Fasitibant prevents the bradykinin and interleukin 1β synergism on prostaglandin E₂ release and cyclooxygenase 2 expression in human fibroblast-like synoviocytes. | 2012 Aug |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT02205814
Unknown
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22638761
Incubation of synoviocytes with BK induced a sustained production of PGE(2) and transient COX-2 gene expression that were prevented by pretreatment with fasitibant (1 μM, 30 min preincubation).
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
41ELA1U90I
Created by
admin on Sat Dec 16 10:26:14 GMT 2023 , Edited by admin on Sat Dec 16 10:26:14 GMT 2023
|
PRIMARY | |||
|
869880-33-1
Created by
admin on Sat Dec 16 10:26:14 GMT 2023 , Edited by admin on Sat Dec 16 10:26:14 GMT 2023
|
PRIMARY | |||
|
DBSALT002946
Created by
admin on Sat Dec 16 10:26:14 GMT 2023 , Edited by admin on Sat Dec 16 10:26:14 GMT 2023
|
PRIMARY | |||
|
100000175047
Created by
admin on Sat Dec 16 10:26:14 GMT 2023 , Edited by admin on Sat Dec 16 10:26:14 GMT 2023
|
PRIMARY | |||
|
11542414
Created by
admin on Sat Dec 16 10:26:14 GMT 2023 , Edited by admin on Sat Dec 16 10:26:14 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD